The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Body mass index and somatic variants in biliary tract cancers.
 
Layal Al Mahmasani
No Relationships to Disclose
 
Joanne Chou
Stock and Other Ownership Interests - PAIGE.AI (Inst)
Patents, Royalties, Other Intellectual Property - Company Paige.AI MSK has licensed intellectual property related to digital pathology slides and algorithm development to Paige. MSK also holds equity in Paige. AI. (Inst)
 
Marinela Capanu
No Relationships to Disclose
 
Amitabh Srivastava
No Relationships to Disclose
 
Carlie Sigel
No Relationships to Disclose
 
Reem Alsuwailem
No Relationships to Disclose
 
Michael Berger
Honoraria - SOPHiA Genetics
Consulting or Advisory Role - AstraZeneca; PAIGE.AI
Research Funding - Boundless Bio
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Danny Khalil
Consulting or Advisory Role - Abbvie; Akamis Bio; Celldex; PsiOxus Therapeutics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination
 
James Harding
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Yiviva (Inst)